Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
1985 2
1986 3
1987 4
1988 2
1989 7
1990 6
1991 8
1992 9
1993 3
1994 1
1995 4
1996 8
1997 6
1998 7
1999 5
2000 5
2001 6
2002 9
2003 4
2004 12
2005 7
2006 7
2007 11
2008 10
2009 16
2010 27
2011 17
2012 18
2013 19
2014 17
2015 28
2016 25
2017 26
2018 18
2019 15
2020 16
2021 21
2022 18
2023 16
2024 23
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

418 results

Results by year

Filters applied: . Clear all
Page 1
Ifrah Zawar.
[No authors listed] [No authors listed] Lancet Neurol. 2023 Sep;22(9):781. doi: 10.1016/S1474-4422(23)00233-8. Lancet Neurol. 2023. PMID: 37596004 No abstract available.
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Hochhaus A, et al. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. N Engl J Med. 2024. PMID: 38820078 Clinical Trial.
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study. Attal M, et al. N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750. N Engl J Med. 2017. PMID: 28379796 Free PMC article. Clinical Trial.
Editorial.
Ifrah N. Ifrah N. Cancer Radiother. 2022 Feb-Apr;26(1-2):1. doi: 10.1016/j.canrad.2021.08.008. Epub 2021 Dec 22. Cancer Radiother. 2022. PMID: 34953700 No abstract available.
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK. Hills RK, et al. Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. Lancet Oncol. 2014. PMID: 25008258 Free PMC article. Review.
Alosetron.
Butt I, Kasmin F. Butt I, et al. 2024 Jul 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jul 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31971721 Free Books & Documents.
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Hunault M, Pautas C, Bertoli S, Dumas PY, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carré M, Peterlin P, Gallego-Hernanz MP, Lemasle E, Guièze R, Simand C, Turlure P, Huynh A, Leguay T, Devillier R, Quoc SN, Duployez N, Luquet I, Penther D, Celli-Lebras K, Mineur A, Raus N, Gardin C, Socié G, Cahn JY, Ifrah N, Vey N, de Latour RP, Delabesse E, Preudhomme C, Hamel JF, Pigneux A, Récher C, Dombret H. Hunault M, et al. NEJM Evid. 2025 Jul;4(7):EVIDoa2400326. doi: 10.1056/EVIDoa2400326. Epub 2025 Jun 24. NEJM Evid. 2025. PMID: 40552969 Clinical Trial.
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Huguet F, Ducassou S, Lhéritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre E, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V. Simonin M, et al. Blood. 2024 Oct 10;144(15):1570-1580. doi: 10.1182/blood.2023023754. Blood. 2024. PMID: 38848537
418 results